Last updated: September 8, 2026
PF-06826647, also known as ropsacitinib, is an oral selective TYK2 inhibitor developed by Pfizer for immune-mediated and hematologic diseases. Public clinical development has not produced an FDA-approved product, a commercial launch, or a disclosed late-stage registration program. The asset’s commercial value is therefore highly constrained: absent a new sponsor or clinical restart, projected product revenue is effectively zero.
What is the current development status of PF-06826647?
PF-06826647 reached Phase 2 clinical development in ulcerative colitis, plaque psoriasis, myelofibrosis and related myeloproliferative disorders. The program generated clinical activity, but public evidence does not show progression into a pivotal Phase 3 program or a regulatory filing.
| Attribute |
Status |
| Generic name |
Ropsacitinib |
| Development code |
PF-06826647 |
| Sponsor |
Pfizer |
| Mechanism |
Selective TYK2 inhibitor |
| Administration |
Oral |
| Principal clinical areas |
Ulcerative colitis, plaque psoriasis, myelofibrosis and related hematologic disorders |
| FDA approval |
None identified |
| Commercial launch |
None identified |
| Orange Book listing |
None identified |
| Phase 3 registration program |
No publicly documented active program |
| Current commercial revenue |
None |
Ropsacitinib differs mechanistically from deucravacitinib, the approved TYK2 inhibitor marketed as Sotyktu. Deucravacitinib selectively binds the TYK2 regulatory, or JH2, domain. PF-06826647 has been described as an inhibitor of TYK2 signaling with activity against cytokine pathways including interferon and interleukin signaling.
What clinical results were reported for PF-06826647?
Ulcerative colitis
Pfizer evaluated PF-06826647 in adults with moderate-to-severe ulcerative colitis in a randomized Phase 2 study. The trial tested oral dosing over approximately 12 weeks and assessed clinical response, clinical remission, endoscopic improvement and safety.
Publicly reported results indicated evidence of biological and clinical activity, particularly in some secondary endpoints. The efficacy profile did not lead to a disclosed Phase 3 ulcerative-colitis program. The available results were not sufficient to establish a commercial position against advanced therapies such as anti-TNF antibodies, vedolizumab, ustekinumab, ozanimod, upadacitinib or approved TYK2 therapy.
Plaque psoriasis
A Phase 2 study evaluated PF-06826647 in moderate-to-severe plaque psoriasis. The program showed dose-related improvement in psoriasis outcomes, including PASI responses, but the development profile remained immature relative to established biologics and later-stage oral competitors.
The psoriasis market has high treatment expectations. A new oral therapy generally needs a clear differentiation in efficacy, safety, convenience, or price. PF-06826647 did not reach a publicly documented regulatory submission in psoriasis.
Myelofibrosis and myeloproliferative neoplasms
PF-06826647 was also studied in myelofibrosis and related hematologic conditions. The scientific rationale involved inhibition of inflammatory cytokine signaling and potential effects on disease-associated symptoms and spleen burden.
The hematology program faced a difficult competitive environment. Ruxolitinib, fedratinib, pacritinib and momelotinib had established or emerging positions in myelofibrosis, while investigational agents were targeting anemia, fibrosis, disease modification and combination treatment. No commercial approval for PF-06826647 has been reported.
When did PF-06826647 lose exclusivity?
PF-06826647 has no publicly established U.S. regulatory exclusivity date because it has not been approved by the FDA.
Patent exclusivity is different from regulatory exclusivity. Patent families may cover the compound, salts, polymorphs, formulations, methods of treatment and manufacturing processes even when a drug is never approved. Publicly available development information does not establish an active, commercially meaningful patent estate that would support a launch forecast.
| Exclusivity category |
PF-06826647 status |
| New chemical entity exclusivity |
Not applicable without FDA approval |
| Orphan-drug exclusivity |
No publicly documented U.S. approval |
| Orange Book-listed patents |
None identified |
| Patent-term restoration |
None identified |
| Patent expiration relevant to generic launch |
No commercially operative date established |
| Biosimilar exclusivity |
Not applicable; PF-06826647 is a small molecule |
Because no branded product was launched, the conventional question of when generic entry occurs does not apply. Any future development would require a fresh assessment of surviving compound and use patents, patent-term adjustments, terminal disclaimers and jurisdiction-specific prosecution status.
What is the FDA and Orange Book status of PF-06826647?
PF-06826647 is not an FDA-approved drug. It therefore does not have an FDA-approved label, an NDA approval date, or an Orange Book-listed reference product.
The absence of an Orange Book listing means:
- No approved reference listed drug exists for an ANDA applicant to copy.
- No Orange Book patent certification pathway is currently tied to PF-06826647.
- No Paragraph IV litigation involving an approved PF-06826647 product can be expected on the public record.
- Any future U.S. development would proceed through a new drug application and would require new regulatory and commercial investment.
Are there Paragraph IV challenges or patent lawsuits involving PF-06826647?
No commercially significant Paragraph IV challenge or branded-product patent litigation has been publicly established for PF-06826647.
Paragraph IV litigation generally follows FDA approval and Orange Book listing. Since PF-06826647 has neither, the standard generic challenge framework is not active. Patent disputes could still arise over clinical-use patents or development rights, but no major public litigation record has defined the asset’s current value.
What formulations and methods of use are protected?
Public development records associate PF-06826647 primarily with oral administration and systemic TYK2 inhibition. The clinically relevant protection categories would likely include:
- Composition-of-matter claims covering the active molecule.
- Pharmaceutical-composition claims covering oral dosage forms.
- Methods of treating ulcerative colitis and psoriasis.
- Methods of treating myelofibrosis or other myeloproliferative disorders.
- Dosing regimens and combination therapies.
- Solid-state, salt or manufacturing claims, if separately pursued.
The commercial importance of these categories depends on whether valid claims remain in force and whether any claim scope covers a clinically useful dose. Without an approved product or an identified active patent family with verified expiration dates, the patent estate cannot be assigned a high-confidence blocking assessment.
How strong is the PF-06826647 patent estate?
The patent estate has limited observable commercial strength because clinical advancement, not merely patent duration, determines practical value.
Positive factors
- Pfizer originated the program and likely pursued foundational compound and use claims.
- Early patent filings would have created a potentially long period before ordinary patent expiration.
- Multiple disease indications could support separate method-of-use positions.
Limiting factors
- No approved product creates no established market franchise.
- No publicly documented Phase 3 program reduces the value of later-filed formulation and method patents.
- TYK2 inhibitor claims face crowded prior art and competing molecules.
- A generic or competitor could potentially design around indication-specific claims if composition-of-matter protection is weak, expired or unenforceable.
- Patent value is reduced if Pfizer has stopped active development or abandoned key jurisdictions.
On the available public record, PF-06826647 should be classified as a dormant or low-commercial-visibility asset rather than a near-term patent-protected launch candidate.
Which companies challenge PF-06826647 commercially?
No company is publicly challenging PF-06826647 through a generic or biosimilar launch because the drug has not reached the market. The relevant competitive set is the broader TYK2 and immune-disease market.
| Competitor |
Company |
Position |
| Sotyktu, deucravacitinib |
Bristol Myers Squibb |
FDA-approved TYK2 inhibitor for plaque psoriasis |
| Vtama, tapinarof |
Dermavant, later associated with other ownership changes |
Nonsteroidal topical psoriasis therapy |
| Rinvoq, upadacitinib |
AbbVie |
JAK inhibitor used across inflammatory diseases |
| Xeljanz, tofacitinib |
Pfizer |
JAK inhibitor with inflammatory-disease indications |
| Jakafi, ruxolitinib |
Incyte |
JAK inhibitor used in myelofibrosis and other diseases |
| Ojjaara, momelotinib |
GlaxoSmithKline |
Approved myelofibrosis therapy, including anemia-related use |
| Vonjo, pacritinib |
CTI BioPharma, acquired by Orphan Biovitrum |
Myelofibrosis therapy for patients with severe thrombocytopenia |
Sotyktu is the closest commercial comparator by mechanism. The JAK inhibitors are more relevant for indication-level competition, particularly in ulcerative colitis and myelofibrosis.
What is the market projection for PF-06826647?
Base-case projection: no commercial revenue
The base case is no launch and no product revenue. This reflects the absence of an FDA approval, commercial supply chain, disclosed Phase 3 development and public launch plan.
| Scenario |
Probability direction |
Commercial result |
| Dormant program remains inactive |
Highest |
$0 product revenue |
| Pfizer licenses or revives the program |
Low |
Revenue delayed by clinical and regulatory development |
| New indication development |
Low |
Potential value only after new Phase 2/3 evidence |
| Direct commercial launch without major new trials |
Very low |
Not credible under standard FDA requirements |
Upside case: strategic revival
A licensee could revive the asset if it obtained convincing efficacy data, clean long-term safety data and enforceable patent protection. The most plausible commercial areas would be:
- Ulcerative colitis, if efficacy can compete with oral JAK inhibitors and biologics.
- Psoriasis, only with a meaningful efficacy or safety advantage over Sotyktu and established biologics.
- Myelofibrosis, if the drug demonstrates anemia, spleen or symptom benefits in a differentiated population.
A revival would require additional clinical investment, manufacturing validation, regulatory interaction and likely a new pivotal program. The earliest commercial revenue would be several years after a restart, not immediately after licensing.
How does PF-06826647 compare with deucravacitinib?
| Factor |
PF-06826647 |
Deucravacitinib |
| Sponsor |
Pfizer |
Bristol Myers Squibb |
| Regulatory status |
No approval |
FDA approved |
| Brand |
None |
Sotyktu |
| Primary established market |
None |
Plaque psoriasis |
| Commercial infrastructure |
None identified |
Established |
| Competitive proof |
Phase 2 clinical evidence |
Commercial and regulatory validation |
| Generic-entry framework |
Not active |
Patent and regulatory exclusivity analysis applies |
| Near-term revenue |
None |
Existing product sales |
Deucravacitinib has a decisive commercial advantage because it has regulatory approval, a label, market access infrastructure and physician adoption. PF-06826647 would need new clinical evidence to compete, not merely a patent position.
What generic launch risks exist?
There is no immediate generic launch risk because no reference product exists. If PF-06826647 were revived and approved, generic risk would depend on:
- Remaining composition-of-matter patent life.
- Scope and duration of method-of-use claims.
- Whether a formulation patent covers the marketed dosage form.
- The ability of an ANDA applicant to carve out patented indications.
- The existence of non-infringing polymorphs, salts or manufacturing routes.
- Any pediatric, orphan or other FDA regulatory exclusivity.
Biosimilar risk is irrelevant because PF-06826647 is a small-molecule drug, not a biologic.
What are the key investment conclusions?
PF-06826647 has scientific validation as a TYK2 inhibitor but lacks the commercial milestones that support a conventional product forecast. Its value is option-based rather than revenue-based.
The asset could retain strategic value if Pfizer holds enforceable composition-of-matter rights and if archived clinical data show a differentiated benefit in a high-value indication. Public information does not establish that either condition is sufficient to justify a near-term valuation.
Key Takeaways
- PF-06826647, or ropsacitinib, is an oral TYK2 inhibitor discovered and developed by Pfizer.
- It reached Phase 2 in ulcerative colitis, psoriasis and hematologic disorders.
- No FDA approval, Orange Book listing, commercial launch or active Phase 3 program has been publicly established.
- No standard Paragraph IV or generic-launch pathway is active.
- The base-case product revenue forecast is zero because the asset has not reached commercialization.
- A strategic revival would require new clinical development and would face strong competition from Sotyktu, JAK inhibitors and established biologics.
- Patent value cannot be treated as commercial exclusivity without verified surviving claims and a regulatory path.
FAQs
Is PF-06826647 the same drug as ropsacitinib?
Yes. PF-06826647 is the development code for ropsacitinib, Pfizer’s investigational oral TYK2 inhibitor.
Can PF-06826647 be prescribed today?
No. It has no FDA-approved indication and is not marketed as a prescription medicine.
Is PF-06826647 a JAK inhibitor?
It targets TYK2, a member of the Janus kinase family, but it was developed as a selective TYK2 inhibitor rather than as a conventional pan-JAK inhibitor.
Could PF-06826647 compete with Sotyktu?
Only if development resumes and new trials show a clinically meaningful advantage in efficacy, safety, dosing or cost. Sotyktu has the stronger current position because it is approved and commercialized.
Does PF-06826647 have biosimilar competition?
No. PF-06826647 is a small molecule, so any future competition would involve generic-drug pathways rather than biosimilars.
References
-
ClinicalTrials.gov. (n.d.). Study of PF-06826647 in participants with moderate to severe ulcerative colitis. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
ClinicalTrials.gov. (n.d.). Study of PF-06826647 in participants with moderate to severe plaque psoriasis. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Bristol Myers Squibb. (2022). U.S. Food and Drug Administration approves Sotyktu, the first and only TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. https://news.bms.com/
-
Pfizer Inc. (n.d.). Pipeline. https://www.pfizer.com/science/drug-product-pipeline.
